LUX(TM) (Light Upon eXtension) reagents are an essential starting point for a broad scope of drug discovery and molecular diagnostic applications including gene expression studies, biomarker analysis and functional genomics experiments. By providing improved sensitivity and specificity over traditional methods of analysis and the ability to examine multiple targets in one experiment, LUX(TM) was developed to meet the demanding needs of these varied applications.
"As we continue to rapidly increase our real-time products menu, access to Invitrogen's LUX(TM) platform is an important milestone," said Tom Shannon, President & CEO of Prodesse. "Now we can provide our customers with a technology that has significant design flexibility as well the tremendous advantage of conveying service rights that do not carry royalty burdens to end users."
"Invitrogen's partnership with Prodesse is a natural evolution of our proven technology platforms and allows us to better serve our customers through collaborations with innovative diagnostic providers," said Gregory T. Lucier, Chairman and CEO of Invitrogen Corporation. "Scientists in basic research and drug discovery and development have already found our LUX technology to produce more reliable data than many of the other quantitative PCR chemistries available. Our partnership will broaden the reach of this technology into clinical laboratories around the world."
Licensing and cost constraints have limited many companies in the molecular diagnostics market. Invitrogen's unique technologies enable companies like Prodesse to provide their customers with state-of-the-art molecular diagnostic products. Invitrogen's LUX(TM) technology, combined with SuperScript® III Reverse Transcriptase and the new Platinum® Tfi DNA Polymerase, provides a powerful and complete solution for assay development.
For additional information, please visit Prodesse at booth # 106 and Invitrogen at booth # 2071 and 2072 at the American Association of Clinical Chemistry (AACC) Annual Lab Expo July 23-26, 2006 in Chicago, IL. AACC is an international scientific/medical society of clinical laboratory professionals, physicians, research scientists and other individuals involved with clinical chemistry and related disciplines. Founded in 1948, the society has 10,000 members and is headquartered in Washington, DC.
About Prodesse
Prodesse is a biotechnology company focused on developing analyte specific reagents that can be used by CLIA certified laboratories to develop assays for detecting infectious disease pathogens. Prodesse currently offers a variety of different products covering 33 different organisms. The company's products can be used on multiple detection platforms. The Company sells its reagents to laboratories throughout the US and the world, and also operates a CLIA certified laboratory for testing services in the Midwest area. For more information about Prodesse and its products, call 888-589-6974 or go to www.prodesse.com.
About Invitrogen Corporation
Invitrogen Corporation (NASDAQ:IVGN - News) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, bioinformatics and cell biology -- placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, California, and conducts business in more than 70 countries around the world. The company globally employs approximately 4,800 scientists and other professionals and had revenues of approximately $1.2 billion in 2005. For more information, visit www.invitrogen.com.
Safe Harbor Statement
Certain statements contained in this press release are considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, and it is Invitrogen's intent that such statements be protected by the safe harbor created thereby. Forward-looking statements include, but are not limited to, the statement that this partnership will broaden the reach of this technology into clinical laboratories around the world. Potential risks and uncertainties include, but are not limited to, the risk that the collaboration will not successfully extend the reach of Invitrogen's technologies, as well as other risks and uncertainties detailed from time to time in Invitrogen's Securities and Exchange Commission filings.
Contact:
Invitrogen Corporation Eric Endicott, 760-268-7438 eric.endicott@invitrogen.com or
Porter Novelli Life Sciences Carolyn Hawley, 858-527-3484 chawley@pnlifesciences.com or
Prodesse, Inc. Andy Shrago, 262-446-0700 x106 ashrago@prodesse.com
Source: Invitrogen Corporation
